Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Business / Medtronic invests in ICE technologies
Business strategic investment

Medtronic invests in ICE technologies

Analysis based on 6 articles · First reported Jun 03, 2026 · Last updated Jun 03, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The strategic investments by Medtronic are expected to positively impact Medtronic's stock price by strengthening its cardiac ablation business and expanding its technology portfolio. This move enhances Medtronic's competitive position in the electrophysiology market, potentially leading to increased market share and revenue growth.

Medical Devices Healthcare Technology
Event Summary

Medtronic plc announced strategic investments in two privately held companies, Beluga Medical and CardioACC, on June 3, 2026. These investments are focused on developing intracardiac echocardiography (ICE) catheter technologies, which provide real-time, high-resolution imaging during electrophysiology procedures for cardiac arrhythmias. Medtronic plans to integrate ICE into its Affera mapping and ablation system to enhance its differentiated value proposition. Beluga Medical is a premarket-stage company in California, while CardioACC is an early commercial-stage company in Shenzhen, China, which received China — National Medical Products Administration approval for its ICE system in 2025. These investments aim to support the future expansion of Medtronic's cardiac ablation portfolio and reinforce its leadership in the electrophysiology market.

Key Actions
100 Medtronic announced strategic investments
90 Medtronic intends to integrate
50 CardioACC received approval
Entities Involved
stock
Medtronic
Medtronic made strategic investments in two privately held companies to enhance its cardiac ablation business and integrate intracardiac echocardiography (ICE) into its Affera mapping and ablation system, aiming to strengthen its leadership in electrophysiology.
Importance 100 Sentiment 70
priv
Beluga Medical
Beluga Medical, a premarket-stage company, received strategic investment from Medtronic to develop a next-generation ICE product, which will be integrated into Medtronic's Affera system.
Importance 70 Sentiment 60
oth
CardioACC
CardioACC, an early commercial-stage company, received strategic investment from Medtronic to further develop its ICE system, which will be integrated into Medtronic's Affera system.
Importance 70 Sentiment 60
per
Rebecca Seidel
Rebecca Seidel, president of Medtronic's Cardiac Ablation Solutions business, commented on the demand for better technologies in electrophysiology and the strategic importance of these investments for Medtronic's long-term portfolio roadmap.
Importance 30 Sentiment 0
per
Khaldoun Tarakji
Khaldoun Tarakji, chief medical officer of Medtronic's Cardiac Ablation Solutions business, highlighted the essential role of intracardiac echocardiography in electrophysiology and how these investments will strengthen the Affera ecosystem.
Importance 30 Sentiment 0
govactor
China — National Medical Products Administration
The China — National Medical Products Administration approved CardioACC's ICE system in 2025, indicating regulatory acceptance of the technology.
Importance 10 Sentiment 0
cnt
China
CardioACC, one of the companies Medtronic invested in, is based in Shenzhen, China, and received approval for its ICE system from the China — National Medical Products Administration.
Importance 10 Sentiment 0
cnt
United States
Beluga Medical, one of the companies Medtronic invested in, is located in California, United States. The Sphere-9 catheter is approved in the U.S., and the Sphere-360 catheter is investigational in the United States.
Importance 10 Sentiment 0
loc
Europe
The Sphere-9 catheter and Sphere-360 catheter, part of Medtronic's Affera system, are approved in Europe.
Importance 10 Sentiment 0
cnt
Australia
The Sphere-9 catheter, part of Medtronic's Affera system, is approved in Australia.
Importance 10 Sentiment 0
cnt
New Zealand
The Sphere-9 catheter, part of Medtronic's Affera system, is approved in New Zealand.
Importance 10 Sentiment 0
cnt
Japan
The Sphere-9 catheter, part of Medtronic's Affera system, is approved in Japan.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.